The Bristol Myers Squibb-backed oncology drug developer ultimately raised nearly $144m in its initial public offering.

Ikena Oncology, a US-based cancer therapy developer backed by pharmaceutical firm Bristol Myers Squibb (BMS), has closed its initial public offering at almost $144m. The company had issued more than 7.81 million shares priced at $16.00 each last month, and they doubled in price to $32.00 by the end of their first day of trading.…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.